Single Cyclists

Technology Integration Streamlines Supplement Management for Healthcare Practices Modern healthcare practices require technology solutions that reduce administrative burden while maintaining clinical oversight. Fullscript’s platform addresses these needs through integrated supplement management tools that connect providers directly with patient adherence data. Dr. Chris Oswald, a platform user since 2014, explained the operational impact: “Fullscript lets patients […]

Simcha Hyman, the founder and CEO ofan investment firm specializing in healthcare innovation, has built a career on identifying opportunities to leverage technology for the betterment of healthcare services. His approach centers on reducing administrative costs and improving efficiency through artificial intelligence. By focusing on automation in areas such as billing, documentation, and decision support, […]

Anavex Life Sciences is making significant strides in the treatment of Parkinson’s disease with their investigational therapy, Anavex 2-73. This novel therapy has shown promising results in reducing the severity of both motor and non-motor symptoms associated with Parkinson’s disease dementia.   In a recent extension study following the Phase 2 ANAVEX 2-73-PDD-001 trial, participants […]

Anavex Life Sciences has recently announced significant progress in the treatment of Parkinson’s disease dementia (PDD) through its investigational drug, blarcamesine. The company’s Phase 2 extension study, despite initial setbacks due to the COVID-19 pandemic, demonstrated notable efficacy and safety over a 48-week period.   Patients who participated in the open-label extension of the study […]

Anavex Life Sciences continues to make significant strides in the realm of neurodegenerative disease treatment, particularly concerning Alzheimer’s disease. The company’s recent Phase 2b/3 clinical trial results have positioned its investigational drug, blarcamesine (ANAVEX®2-73), as a promising candidate in the fight against this debilitating condition.  The trial, conducted across multiple countries, involved 508 participants diagnosed […]

Anavex Life Sciences has announced encouraging results from their recent phase 2b/3 clinical trial, bringing new hope to those affected by early Alzheimer’s disease. The investigational agent, blarcamesine (ANAVEX®2-73), demonstrated significant efficacy in reducing amyloid-ß biomarkers and slowing neurodegeneration among study participants. The multicenter, randomized, double-blind, placebo-controlled trial included 508 participants diagnosed with early symptomatic […]

On September 15, 2023, groundbreaking data from a phase 2b/3 clinical trial revealed that the investigational medication blarcamesine, developed by Anavex Life Sciences, significantly reduces amyloid-ß biomarkers in patients with early Alzheimer’s disease. The findings were made public by Anavex Life Sciences, highlighting the potential of blarcamesine to alter the course of this debilitating condition.  […]

Anavex Life Sciences has unveiled promising outcomes from the open-label extension of its Phase 2 study on blarcamesine (ANAVEX2-73) for Parkinson’s disease dementia (PDD). The 48-week study demonstrated the safety and efficacy of the investigational drug, providing a glimmer of hope for patients grappling with this debilitating condition.  The extension phase faced delays due to […]